The CEO of Lilly says that the US pharmaceutical market needs to be reformed before drug prices can be adjusted.
David Ricks, CEO of Lilly, said during an analyst conference call on Thursday that the U.S. pharmaceutical market structure is in urgent need of "emergency reform" before implementing any substantive drug pricing reforms.
Latest